These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 18063025)

  • 1. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.
    Lim SS; Gaziano TA; Gakidou E; Reddy KS; Farzadfar F; Lozano R; Rodgers A
    Lancet; 2007 Dec; 370(9604):2054-62. PubMed ID: 18063025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
    Gaziano TA; Opie LH; Weinstein MC
    Lancet; 2006 Aug; 368(9536):679-86. PubMed ID: 16920473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The burden and costs of chronic diseases in low-income and middle-income countries.
    Abegunde DO; Mathers CD; Adam T; Ortegon M; Strong K
    Lancet; 2007 Dec; 370(9603):1929-38. PubMed ID: 18063029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
    Grover S; Coupal L; Lowensteyn I
    Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries.
    Yoo SGK; Chung GS; Bahendeka SK; Sibai AM; Damasceno A; Farzadfar F; Rohloff P; Houehanou C; Norov B; Karki KB; Azangou-Khyavy M; Marcus ME; Aryal KK; Brant LCC; Theilmann M; Cífková R; Lunet N; Gurung MS; Mwangi JK; Martins J; Haghshenas R; Sturua L; Vollmer S; Bärnighausen T; Atun R; Sussman JB; Singh K; Saeedi Moghaddam S; Guwatudde D; Geldsetzer P; Manne-Goehler J; Huffman MD; Davies JI; Flood D
    JAMA; 2023 Aug; 330(8):715-724. PubMed ID: 37606674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is inequality at the heart of it? Cross-country associations of income inequality with cardiovascular diseases and risk factors.
    Kim D; Kawachi I; Hoorn SV; Ezzati M
    Soc Sci Med; 2008 Apr; 66(8):1719-32. PubMed ID: 18280021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
    Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
    BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, content and financing of an essential national package of health services.
    Bobadilla JL; Cowley P; Musgrove P; Saxenian H
    Bull World Health Organ; 1994; 72(4):653-62. PubMed ID: 7923544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we prevent cardiovascular diseases in low- and middle-income countries?
    Lenfant C
    Bull World Health Organ; 2001; 79(10):980-2; discussion 983-7. PubMed ID: 11693981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
    Bautista LE; Vera-Cala LM; Ferrante D; Herrera VM; Miranda JJ; Pichardo R; Sánchez Abanto JR; Ferreccio C; Silva E; Oróstegui Arenas M; Chirinos JA; Medina-Lezama J; Pérez CM; Schapochnik N; Casas JP
    Health Aff (Millwood); 2013 Jan; 32(1):155-64. PubMed ID: 23297283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scaling up interventions for chronic disease prevention: the evidence.
    Gaziano TA; Galea G; Reddy KS
    Lancet; 2007 Dec; 370(9603):1939-46. PubMed ID: 18063028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
    Troche CJ; Tacke J; Hinzpeter B; Danner M; Lauterbach KW
    Eur Heart J; 1998 Apr; 19 Suppl C():C59-65. PubMed ID: 9597427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.